MAPT and Alzheimer disease: Plasma tau concentrations in AD and controls are below the level of detection of the most commonly used tau assays, and plasma Aβ42 [8]–[11] and plasma chromogranin A (R.Perrin et al., unpublished data) concentrations show no significant differences among CDR groups.